Kemena (Ectinib Hydrochloride Tablets) is suitable for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (non-small cell lung cancer) with sensitive mutation of epidermal growth factor receptor (EGFR) gene.
Kemena can be used to treat locally advanced or metastatic non-small cell lung cancer (NSCLC), after receiving at least one chemotherapy regimen failed. Previous chemotherapy mainly refers to platinum-based combination chemotherapy. This product is not recommended for patients with EGFR wild-type non-small cell lung cancer.
Extended data
The recommended dosage is125mg each time (1tablet), three times a day. Oral, fasting or eating with food, high-calorie food may significantly increase the absorption of drugs.
Dose adjustment: when patients have unbearable adverse reactions such as rash and diarrhea, they can stop taking the drug (1-2 weeks) until the symptoms are relieved or disappeared; Subsequently, the dose of 125mg/ tablet (1 tablet) was resumed, three times a day.
Patients with slight elevation of transaminase (ALT[ alanine aminotransferase] and AST[ aspartate aminotransferase] below 100 IU/L) can continue to take medicine, but they should be closely monitored.
Patients with obviously increased transaminase (both ALT and AST are above 100 IU/L) can suspend administration, closely monitor transaminase, and resume administration when transaminase recovers (both ALT and AST are below 100 IU/L or normal).
The analysis of blood drug concentration data of patients with different ages and genders shows that the blood drug concentration of patients is not affected by factors such as age and gender, so it is not recommended to adjust the dose according to age and gender.
Special population: There are no clinical research results for children or pregnant women. Clinical research on elderly patients and patients with hepatic and renal insufficiency is under way.
reference data
Baidu Encyclopedia-Kai Myna